Premium
IC‐P2‐106: Diagnosing, tracking and evaluation of treatment response for Alzheimer's disease using EEG and database‐ supported diagnostics
Author(s) -
Johnsen Kristinn,
Johannesson Gisli,
Emilsdottir Asdis,
Blin Nicolas,
Helgadóttir Halla,
Snaedal Jon,
Gudmundsson Thorkell
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.099
Subject(s) - electroencephalography , disease , medicine , classifier (uml) , dementia , surrogate endpoint , audiology , artificial intelligence , computer science , psychiatry
and mild cognitive impairment (MCI) in comparison with healthy subjects. The most prominent change is the reduction of the neuronal marker N-acetylaspartate (NAA). Recent studies have shown that low NAA levels predict cognitive decline in MCI. Furthermore, NAA increases during acetylcholinesterase-inhibitor treatment in AD. Thus, 1H-MRS measures may be candidates for a biomarkers or surrogate markers in clinical trials. A prerequisite for the application of 1H-MRS in large clinical trials is the multicenter feasibility. Methods: Within the German Competence Network on Dementia, we performed the first 1H-MRS multicenter study of the medial temporal lobe, as a region of particular interest in AD and MCI patients. The study was conducted at four German sites. We measured metabolic ratios and quantities of different molecular groups (NAA, choline compounds, creatine/phosophcreatine, myoinositol, glutamine/glutamate). In the presentation, the data from the crossectional study will be reported. The sample included 125 patients with dementia, 123 MCI patients and 48 comparison subjects. Results: We observed center effects for different metabolites and ratios. Z-transformed data, however, showed difference between diagnostic groups. A main result is a significant group effect on the metabolic ratio NAA/Cr with AD patients showing significantly lower measures than the healthy comparison subjects and MCI patients showing measures in between. The detailed results will be given in the presentation. Conclusions: Our study shows that multicenter 1H-MRS of the medial temporal lobe in patients with mild AD and MCI can be performed, which is the basis of 1H-MRS as a biomarker or surrogate marker tool in clinical trials.